JP2017522352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522352A5 JP2017522352A5 JP2017505440A JP2017505440A JP2017522352A5 JP 2017522352 A5 JP2017522352 A5 JP 2017522352A5 JP 2017505440 A JP2017505440 A JP 2017505440A JP 2017505440 A JP2017505440 A JP 2017505440A JP 2017522352 A5 JP2017522352 A5 JP 2017522352A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- group
- salt
- independently represent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 201000009267 bronchiectasis Diseases 0.000 claims description 6
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 5
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 4
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 4
- 206010069351 acute lung injury Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 3
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 claims description 2
- 101710087078 Dipeptidyl peptidase 1 Proteins 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 208000027004 Eosinophilic disease Diseases 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims description 2
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 claims description 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 claims description 2
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 2
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229940121647 egfr inhibitor Drugs 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 244000000010 microbial pathogen Species 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 230000003448 neutrophilic effect Effects 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000007474 aortic aneurysm Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003073 chemokine receptor CCR9 antagonist Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14179458 | 2014-08-01 | ||
| EP14179458.6 | 2014-08-01 | ||
| PCT/EP2015/067271 WO2016016242A1 (en) | 2014-08-01 | 2015-07-28 | Substituted oxetanes and their use as inhibitors of cathepsin c |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522352A JP2017522352A (ja) | 2017-08-10 |
| JP2017522352A5 true JP2017522352A5 (enExample) | 2018-09-06 |
| JP6529575B2 JP6529575B2 (ja) | 2019-06-12 |
Family
ID=51266130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505440A Active JP6529575B2 (ja) | 2014-08-01 | 2015-07-28 | 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9440960B2 (enExample) |
| EP (1) | EP3174879B1 (enExample) |
| JP (1) | JP6529575B2 (enExample) |
| WO (1) | WO2016016242A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| CA3089240A1 (en) * | 2018-02-07 | 2019-08-15 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides |
| SI3758708T1 (sl) | 2018-03-01 | 2025-04-30 | Astrazeneca Ab | Farmacevtski sestavki, ki vsebujejo (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil}-1,4-oksazepan-2-karboksamid |
| CA3106269A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| WO2022020245A1 (en) | 2020-07-20 | 2022-01-27 | Insmed, Inc. | Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions |
| MX2023002371A (es) | 2020-08-26 | 2023-05-19 | Haisco Pharmaceuticals Pte Ltd | Derivado de nitrilo que actua como inhibidor de la dipeptidil peptidasa 1 y uso del mismo. |
| CN116438200A (zh) | 2020-09-10 | 2023-07-14 | 普雷西里克斯公司 | 针对fap的抗体片段 |
| CN116783189B (zh) * | 2021-02-05 | 2026-01-30 | 上海复星医药产业发展有限公司 | 含1，4-氧杂氮杂环庚烷的并环类衍生物 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| JP2025517625A (ja) | 2022-05-02 | 2025-06-10 | プレシリックス・ナームローゼ・ベンノートシヤープ | プレターゲティング |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| CN120957728A (zh) | 2023-03-23 | 2025-11-14 | 海思科医药集团股份有限公司 | 一种二肽基肽酶小分子抑制剂的药物组合物 |
| AU2024308862A1 (en) | 2023-06-27 | 2026-02-12 | Haisco Pharmaceuticals Pte. Ltd. | Dpp1 inhibitor intermediate, and preparation method therefor and use thereof in medicines |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4125727A (en) | 1976-10-18 | 1978-11-14 | American Cyanamid Company | Method of preparing imidazoisoindolediones |
| US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| US7012075B2 (en) | 2001-03-02 | 2006-03-14 | Merck & Co., Inc. | Cathepsin cysteine protease inhibitors |
| JP2006527704A (ja) * | 2003-06-18 | 2006-12-07 | プロザイメックス・アクティーゼルスカブ | プロテアーゼ阻害剤 |
| TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
| US20060223846A1 (en) | 2005-03-08 | 2006-10-05 | Dyatkin Alexey B | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
| CA2602112A1 (en) * | 2005-03-22 | 2006-09-28 | Celera Genomics | Sulfonyl containing compounds as cysteine protease inhibitors |
| WO2009047829A1 (ja) | 2007-10-12 | 2009-04-16 | Fujitsu Limited | Ｉｐ電話自動試験システム及び方法 |
| BRPI0820665A2 (pt) | 2007-12-12 | 2018-05-29 | Astrazeneca Ab | compostos de peptidil nitrilas, processos para fabricação dos mesmos, composição farmacêutica, combinação e uso de ditos compostos |
| AU2010244218B2 (en) | 2009-05-07 | 2012-07-19 | Astrazeneca Ab | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
| WO2010142985A1 (en) * | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
| US8524710B2 (en) * | 2010-11-05 | 2013-09-03 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
| WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
| US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| GEP201706780B (en) * | 2013-03-14 | 2017-11-27 | Boehringer Ingelheim Int | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| UA118610C2 (uk) * | 2014-09-12 | 2019-02-11 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Спіроциклічні інгібітори катепсину c |
-
2015
- 2015-07-28 JP JP2017505440A patent/JP6529575B2/ja active Active
- 2015-07-28 WO PCT/EP2015/067271 patent/WO2016016242A1/en not_active Ceased
- 2015-07-28 EP EP15739650.8A patent/EP3174879B1/en active Active
- 2015-07-31 US US14/814,759 patent/US9440960B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522352A5 (enExample) | ||
| JP2017526716A5 (enExample) | ||
| JP2014526492A5 (enExample) | ||
| JP6508544B2 (ja) | 腫瘍を治療するための薬用組成物 | |
| JP2016516020A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| JP2016510785A5 (enExample) | ||
| JP2012504133A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2016515110A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2011523412A5 (enExample) | ||
| JP2009514874A5 (enExample) | ||
| JP2010523722A5 (enExample) | ||
| CA3053991A1 (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| JP2014500295A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2015524807A5 (enExample) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2016510784A5 (enExample) | ||
| JP2011500621A5 (enExample) | ||
| JP2017533930A5 (enExample) | ||
| JP2011507896A5 (enExample) | ||
| IL234262A (en) | Pharmaceuticals containing ccr3 inhibitors | |
| CN102655859A (zh) | 病毒感染的组合疗法治疗 |